跳至主要内容
临床试验/NCT04182425
NCT04182425已完成不适用

Real-life Study to Assess the Incidence of Allergic Manifestations and Infectious Episodes in Healthy Term Infants at Risk of Dysbiosis During the First Year of Life

Bledina1 个研究点 分布在 1 个国家目标入组 334 人开始时间: 2019年12月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Bledina
入组人数
334
试验地点
1
主要终点
Cumulative incidence of atopic dermatitis in the infants included in the study

研究概览

简要总结

This study will evaluate the incidence of allergic manifestations (the first of which is atopic dermatitis) and infectious diseases in children fed with an infant formula under real conditions of use.

详细描述

The primary objective of the study is to evaluate the cumulative incidence of atopic dermatitis in healthy infants at risk for dysbiosis at 12 months of age and to identify factors associated with the presence of atopic dermatitis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
— 至 5 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • full-term infant (gestational age ≥ 37 and ≤ 42 weeks) in good health;
  • Having at least one risk factor for dysbiosis, including:
  • birth by caesarean section,
  • Antibiotic exposure between birth and inclusion or in utero (mother who received antibiotics) during the last trimester of pregnancy, or per-partum (mother who received antibiotics during childbirth),
  • a family history of allergy confirmed by a doctor in a family member, affecting at least one of the two parents or siblings (asthma, atopic dermatitis, eczema, allergic rhinitis, proven food allergy);
  • Aged at most 5 weeks;
  • Having a weight in the reference values for gestational age and sex (between the 10th and the 90th percentiles according to the growth curves in force);
  • Already consuming an infant formula (with or without associated breast milk), or whose mother wishes to introduce an infant formula at the end of this consultation to switch to mixed breastfeeding or to start weaning;
  • Authorization of a parent (or both) or legal representative of the child to collect personal information about their child and family.

排除标准

  • Premature infants or low birth weight (< 2500g);
  • Infant allergic to cow's milk protein;
  • Infants with severe congenital anomalies that may impact growth (cystic fibrosis, bronchopulmonary dysplasia, tracheomalacia, tracheoesophageal fistula, congenital heart defects ...);
  • Infants with chronic disease or severe neonatal pathology, or a pathology predisposing to infections (HIV, hepatitis B or C, autoimmune diabetes, immune deficiency, respiratory distress, sepsis, intraventricular hemorrhage, severe neonatal hepatitis, necrotizing enterocolitis, hypertension persistent pulmonary ...), or renal or hepatic pathology;
  • Inability of the parent or legal representative to understand the protocol of the study, or doubts of the physician on the ability or willingness to comply with the protocol.

结局指标

主要结局

Cumulative incidence of atopic dermatitis in the infants included in the study

时间窗: 12 months

Number of episodes of dermatitis reported during the 12 months of follow-up, and objectified by a SCORAD score \> 0.

次要结局

  • Observance(3, 6 and 12 months)
  • Cumulative incidence of infections(3, 6 and 12 months)
  • Consumption(3, 6 and 12 months)
  • Satisfaction with Likert scale(3, 6 and 12 months)
  • Weight(3, 6 and 12 months)
  • Atopic dermatitis(3, 6 and 12 months)
  • Height(3, 6 and 12 months)
  • Cumulative incidence of allergic manifestations(3, 6 and 12 months)
  • Gastrointestinal tolerance(3, 6 and 12 months)
  • Cranial perimeter(3, 6 and 12 months)

研究者

发起方
Bledina
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验